Abstract
Objective Antenatal depression (AD) is the commonest morbidity during pregnancy. There is evidence that premenstrual syndrome (PMS) and AD share common immune-inflammatory pathways. Few studies have assessed the relation between the affective symptoms of PMS and AD. The present study aims to evaluate the association between the severity of depressive PMS and AD in early and late pregnancy.
Methods Women in early pregnancy (<=16 weeks) were recruited and followed until late pregnancy (>=20 weeks). The Premenstrual Symptoms Screening Tool (PSST) was used to assess PMS and AD symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS). Results: The PSST score was significantly and positively associated with the EPDS scores both in early and late pregnancy. Up to 57.6% of the variance in the early EPDS score was explained by the regression on the first factor extracted from 10 depression and anxiety PSST items (dubbed the DepAnx PSST domain), PSST item insomnia, relation dissatisfaction, and the Abuse Assessment Screen item 1 (partner abuse). Additionally, 6.3% of the variance in the PSST DepAnx domain was explained by the regression on the mental-physical neglect score of the Adverse Childhood Experiences Questionnaire. There were specific indirect effects of PSST DepAnx (p<0.001), insomnia (p=0.041), relation dissatisfaction (p=0.023) and partner abuse (p=0.007) on the late EPDS which were mediated by the early EPDS score.
Conclusion The affective, but not psychosomatic, symptoms of PMS strongly predict depressive symptoms during pregnancy suggesting that the pathophysiology of affective PMS symptoms overlap with those of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
the 90th Anniversary of Chulalongkorn University Ratchadapisek Sompoch Fund, and Ratchadapisek Sompoch Endowment Fund (Grant number: RCU_H_64_034_5) and
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Boards (IRBs) at both Khon Kaen Hospital and Chulalongkorn University (KEF62036 and COA No. 280/2019)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Electronic address: wandee.s{at}chula.ac.th.
Data Availability
All data produced in the present work are contained in the manuscript
